Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Brodmann, M; Keirse, K; Scheinert, D; Spak, L; Jaff, MR; Schmahl, R; Li, P; Zeller, T; IN.PACT Global Study Investigators.
Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
JACC-CARDIOVASC INTE. 2017; 10(20): 2113-2123.
Doi: 10.1016/j.jcin.2017.06.018
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Brodmann Marianne
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This study sought to evaluate the safety and effectiveness of a paclitaxel-coated drug-coated balloon (DCB) for the treatment of patients with de novo in-stent restenosis (ISR). Treatment of patients with ISR remains a challenge. Current strategies are plagued by high rates of recurrent restenosis and need for reintervention. The best intervention for ISR remains to be elucidated. The IN.PACT Global study is an independently adjudicated multicenter, prospective, single-arm study that enrolled 1,535 subjects with symptomatic atherosclerotic disease of the superficial femoral and/or popliteal arteries, including de novo ISR lesions. Patients enrolled in the pre-specified ISR imaging cohort were evaluated for vessel patency and reintervention within the 12-month follow-up period. A total of 131 subjects with 149 ISR lesions were included for analysis. The mean age of the cohort was 67.8 years. Mean lesion length was 17.17 ± 10.47 cm, including 34.0% total occlusions and 59.1% calcified lesions. The 12-month Kaplan-Meier estimate of primary patency was 88.7%. The rate of clinically driven target lesion revascularization (CD TLR) at 12 months was 7.3%. The primary safety outcome, a composite of freedom from device- and procedure-related mortality through 30 days and freedom from major target limb amputation and CD TLR within 12 months, was 92.7%. There were no major target limb amputations, no deaths, and a low (0.8%) thrombosis rate. Results from the ISR imaging cohort demonstrate high patency and a low rate of CD TLR at 12 months. These data confirm the safety and effectiveness of the IN.PACT Admiral DCB (Medtronic, Dublin, Ireland) in complex femoropopliteal lesions, including this challenging subset. Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Amputation -
- Angiography -
- Angioplasty, Balloon - adverse effects
- Angioplasty, Balloon - instrumentation
- Angioplasty, Balloon - mortality
- Cardiovascular Agents - administration & dosage
- Cardiovascular Agents - adverse effects
- Coated Materials, Biocompatible -
- Constriction, Pathologic -
- Endovascular Procedures - adverse effects
- Endovascular Procedures - instrumentation
- Endovascular Procedures - mortality
- Female -
- Femoral Artery - diagnostic imaging
- Femoral Artery - physiopathology
- Humans -
- Kaplan-Meier Estimate -
- Limb Salvage -
- Male -
- Middle Aged -
- Paclitaxel - administration & dosage
- Paclitaxel - adverse effects
- Peripheral Arterial Disease - diagnostic imaging
- Peripheral Arterial Disease - mortality
- Peripheral Arterial Disease - physiopathology
- Peripheral Arterial Disease - therapy
- Popliteal Artery - diagnostic imaging
- Popliteal Artery - physiopathology
- Prospective Studies -
- Recurrence -
- Stents -
- Time Factors -
- Treatment Outcome -
- Ultrasonography, Doppler, Duplex -
- Vascular Access Devices -
- Vascular Patency -
- Find related publications in this database (Keywords)
- drug-coated balloon
- femoropopliteal artery
- in-stent restenosis
- paclitaxel
- peripheral artery disease